| abstract |
The present invention is related to an aggregate for use in the treatment of cancer, wherein the aggregate comprisesa) a polyoxazoline comprising at least one terminal group modified with a hydrophobic moiety, wherein said polyoxazoline further comprises a linear portion, a branched portion or both, and said branched portion comprises a symmetrically branched polymer, an asymmetrically branched polymer or a combination thereof; wherein said polyoxazoline comprises a ratio of monomer to initiator is 60:1,b) a taxane, wherein said polyoxazoline and said taxane has a weight ratio of polymer to taxane of 2:1 to 10:1, andc) a size from 50 nm to about 100 nm before lyophilization. |